Bioanalytical Testing Services Market (By Molecule Type: Large Molecule [Immunoassays, LC-MS Studies,Others], Small Molecule; By Test Type: ADME [In-Vitro, In-Vivo], PD, PK, Bioequivalence, Bioavailability, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Published at : April-2019 | Delivery Format : PDF | Status: Published | Pages : 160


A series of methods used to determine the quantity and the metabolites of active drugs in the human body is provided by bioanalytical testing services. It is vital to the development of medicines and to the success of the medicine. During the forecast period, the need for quick action medicines to treat chronic diseases is predicted to boost market demand. Continuous progress in research and development (R&D) supports this process. Rapid biologic development to speed up clinical tests that can directly influence treatment options in cases of severe disease such as cancer. Outsourcing R&D to contract research organizations can lead to large demands on the market for bioanalytical testing services. The report provides analysis of global Bioanalytical Testing Services market for the period 2016-2026, wherein 2019 to 2026 is the forecast period and 2017 is considered as the base year. According to Acumen Research and Consulting, the global Bioanalytical Testing Services market is expected to grow at noteworthy CAGR around 7 % throughout the forecast period and reach around US$ 4.57 billion by 2026.

Market Dynamics

Increased biological development can trigger market demand during the projected time period. The patent expired and necessary clinical trials of various medications can have a positive effect on the market of bioanalytic testing services. Outsourcing testing services in developing economies to contract research organizations can drive market growth over the forecast period. Increased cancer prevalence and other chronic diseases requiring blockbuster medicines can boost market demand in the coming years. However, high drug costs can pose a market growth challenge.

Industry Insights

The increasing frequency with which major pharmaceutical companies are outsourcing R&D activities to concentrate on their core competencies is the key driver. Furthermore, rather than conducting an internal study the economic efficiency offered for outsourcing should continue to boost demand. Most large sellers are patenting that is expected to lead drug manufacturers ' investment in replenishing their pipelines. This is one of the main reasons why the bioanalytical testing services market is growing. Contract Research Organizations (CROs) are not responsible for their growing demand from the pharmaceutical sector by diversifying their expertise compared to pharmaceutical companies with regard to clinical trials in various geographies and drug development in specific therapeutic sectors.

In the pharmaceutical analytical testing services market outsourcing drives significant increase in complexity and the number of standards a single molecules may be required to comply with. In conjunction with changing standards, companies must remain abreast of regulatory updates and use of expertise and advisory services. In addition, the harmonized guidelines are regularly updated by international organizations such as the International Council on Harmonisation (ICH).

Biosimilars, combination molecules and other innovative drugs have led to increased demand for specific test types. Moreover, if businesses diversify to a new site, local standards must be followed, which may necessitate certain types of testing.

Molecule Type Stance

The biological testing services market is divided into small molecules and large molecules based on the type of molecule. In 2018 a lucrative market share for the small molecular sector existed. The majority of the drug compounds generic and branded are in the small group of molecules. In addition, generic manufacturers are required to conduct bioanalytical tests and submit results with the patent expiration of many blockbuster medicines. These factors mainly governed the segment's growth in the next few years.

On the other hand, over this forecast period, a large sector of molecules is expected to show healthy growth. A rich biofuel pipeline or amino acid-based molecules can be attributed to this. Moreover, it requires technical expertise with advanced analytical instruments for testing these molecules. This infrastructure is available from suppliers of bioanalytical services. The externalization of these molecules is therefore likely the dominant trend over the forecast period. The bioanalytical testing is expected.

Large molecules are based on protein with therapeutic effects, also known as biologics. The large molecules consist of several thousand amino acids and can be 150kDa heavy. During the whole development process (market research), bioanalytical testing of large molecular drugs is required. The biological pipeline is rich and over the years, biological sales have increased exponentially.

Test Type Insights

On the basis of the test type, the market is divided into MTS Excretion (ADME), PH, Pharmacokinetics (PD), bioavailability, bioequivalence, and others. The marketplace is divided into In 2018 studies on bioavailability (BA) and bioequivalence (BE), the high demands for such services in the production of generical drugs, led to significant market shares.

Pharmacokinetics (PK) is the post-administration branch of pharmacology associated with the destiny of drugs. PK-parameters are essential and are frequently measured, including dosage interval, peak plasma concentration (Cmax), time to peak plasma concentration (tmax) and volume of disbursement. Companies use advanced methods for PK parameter determination. For example, SGS technology from Dry Blood Spot (DBS) offers numerous advantages over traditional processes. The benefit of DBS methods is the minimum requirement for samples, the absence of post-gathering processing, convenient delivery and storage of samples and low biohazard risks.

Regional Snapshots

The global market for bioanalytical testing services was managed by North America in 2018. This is because it is one of the highly reliable, complex and high-end pharmaceutical manufacturing centers. Therefore, original equipment manufacturers (OEMs) move quickly to manufacturing electronic services providers to handle more electronic components in current pharmaceutical products in an efficient way.

One of the main factors promoting the growth of the market in North America is expected of the rapid increase in pharmaceutical production to meet the growing demand for efficient healthcare. A recent study shows that about 15.0% of GDP in 2013 was spent on health and medicine. As the state support for healthcare costs will increase in the region's pharmaceutical outsourcing market, it is anticipated.

In Asia Pacifique, the growth in outsourcing services in comparatively unrivaled markets is expected to be the most rapid over the forecast period. In this region, the supply centers in China, Manila and India typically support outsourcing services. As an outlet for onshore customers and shore customers from Japan, China becomes more popular.

Market Segmentation

Bioanalytical Testing Services Market by Molecule Type

  • Large Molecule
    • Immunoassays
    • LC-MS Studies
    • Others
  • Small Molecule

Bioanalytical Testing Services Market by Test Type

  • ADME
    • In-Vitro
    • In-Vivo
  • PD
  • PK
  • Bioequivalence
  • Bioavailability
  • Others

Global Bioanalytical Testing Services Market, by Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

The market research study on “Bioanalytical Testing Services Market (By Molecule Type: Large Molecule [Immunoassays, LC-MS Studies,Others], Small Molecule; By Test Type: ADME [In-Vitro, In-Vivo], PD, PK, Bioequivalence, Bioavailability, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Bioanalytical Testing Services market segments with market dynamics and their impact. The report provides insights on global Bioanalytical Testing Services market by product, end use industry and major geographic regions. The report also covers basic technology development policies.

The report offers an overview of the market and statistical diagrams to support the expected figures. Our analysts predict the market scope and future prospects in an insightful way. The Acumen Research and Consulting report contains a comprehensive analysis of the global market in bioanalytical testing services segmented by molecular type, test type and region. The report outlines numerous growth strategies implemented by companies as well as the latest market trends. The market share and current position of all leading players are discussed in detail. It analyzes players ' new revenue sources and highlights the different strategies.

Key Players

The Bioanalytical Testing Services market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are PSC, SGS SA, Toxikon, Inc., The Intertech group, Pace Analytical Services, SLC, PPD ; ICON plc ; Covance Inc. ; LabCorp ; Charles River Laboratories International, Inc.. among others.

The main strategic undertakings of these players are collaborations, service portfolio expansion and merger and acquisitions. In February 2015, for example, Covance was acquired by Laboratory Corporation of America (LabCorp). This transaction is expected to broaden LabCorp's global biopharmaceutical reach and promote higher profit and project numbers.

Cart Summary